James Healy - Jun 10, 2024 Form 4 Insider Report for Rapport Therapeutics, Inc. (RAPP)

Role
Director
Signature
/s/ Cheryl Gault, Attorney-in-Fact
Stock symbol
RAPP
Transactions as of
Jun 10, 2024
Transactions value $
$9,500,008
Form type
4
Date filed
6/10/2024, 07:38 PM
Previous filing
Jun 6, 2024
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RAPP Common Stock Conversion of derivative security $0 +1.39M $0.00 1.39M Jun 10, 2024 By Sofinnova Venture Partners XI, L.P. F1, F2
transaction RAPP Common Stock Purchase $8M +471K +33.79% $17.00* 1.86M Jun 10, 2024 By Sofinnova Venture Partners XI, L.P. F2
transaction RAPP Common Stock Purchase $317K +18.6K $17.00* 18.6K Jun 10, 2024 By Sofinnova Synergy Master Fund LP F3
transaction RAPP Common Stock Purchase $304K +17.9K $17.00* 17.9K Jun 10, 2024 By Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP F4
transaction RAPP Common Stock Purchase $447K +26.3K $17.00* 26.3K Jun 10, 2024 By Crestline Summit Master, SPC - PEAK SP F5
transaction RAPP Common Stock Purchase $433K +25.5K $17.00* 25.5K Jun 10, 2024 By CRESTLINE SUMMIT PINNACLE MASTER, L.P. F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RAPP Series B Preferred Stock Conversion of derivative security $0 -11.9M -100% $0.00* 0 Jun 10, 2024 Common Stock 1.39M By Sofinnova Venture Partners XI, L.P. F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into Common Stock on a one-for-8.5648 basis without payment of consideration. The Series B Preferred Stock had no expiration date.
F2 The shares are directly held by Sofinnova Venture Partners XI, L.P. ("SVP XI"). Sofinnova Management XI, L.P. ("SM XI LP") is the general partner of SVP XI and Sofinnova Management XI, L.L.C. ("SM XI") is the general partner of SM XI LP. The Reporting Person is a managing member of SM XI and may be deemed to share voting and dispositive power over the shares held by SVP XI. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3 The shares are directly held by Sofinnova Synergy Master Fund LP ("Synergy Fund"). Sofinnova Synergy GP, LLC ("Synergy Fund GP") is the general partner of Synergy Fund. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Synergy Fund. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F4 The shares are directly held by Crestline Summit Master, SPC - CRESTLINE SUMMIT APEX SP ("APEX SP"). Synergy Fund GP is the general partner of APEX SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by APEX SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F5 The shares are directly held by Crestline Summit Master, SPC - PEAK SP ("PEAK SP"). Synergy Fund GP is the general partner of PEAK SP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by PEAK SP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F6 The shares are directly held by CRESTLINE SUMMIT PINNACLE MASTER, L.P. ("Pinnacle LP"). Synergy Fund GP is the general partner of Pinnacle LP. The Reporting Person is a managing member of Synergy Fund GP and may be deemed to share voting and dispositive power over the shares held by Pinnacle LP. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.